Scholarlink

Purpose <p>Endovascular treatment (EVT) with a stent retriever is known to be effective and safe in patients with acute ischemic stroke due to large vessel occlusion. We aimed to compare the most used stent retrievers in a nationwide registry of EVT-treated stroke patients (MR CLEAN Registry).</p> Methods <p>Patients with ischemic stroke due to large vessel occlusion, treated with stent retriever thrombectomy (each stent retriever with at least 100 EVTs) as first-line technique in the MR CLEAN Registry, were included. The primary outcome was the modified Rankin Scale (mRS) score at 90-day follow-up. Secondary outcomes included reperfusion (expanded Treatment In Cerebral Infarction [eTICI]), mortality at 90&#xa0;days, symptomatic intracranial hemorrhage, National Institutes of Health Stroke Scale (NIHSS) score between 24 and 48&#xa0;h post-EVT, and procedure time. With multivariable regression analyses, we calculated odds ratios (OR) and β-estimates to compare outcomes between the most frequently used stent retrievers, with adjustments for predefined variables. One subgroup analysis focused on the effect of the stent retriever on outcomes in M1 occlusions.</p> Results <p>Trevo (Stryker) was the most frequently used stent retriever (n = 1541, 70%). Other types were Solitaire (n = 301, 14%) (Medtronic), Embotrap (n = 255, 11%) (Cerenovus; Johnson&amp;Johnson), and Revive (n = 103, 5.2%) (Cerenovus; Johnson&amp;Johnson).</p> <p>There was a slightly, but statistically significant, higher 90-day mRS score (adjusted common [ac]OR: 0.75, 95%CI: 0.57–0.99) and mortality rate (aOR: 1.77, 95%CI: 1.16–2.68) for the Solitaire and longer procedure times for the Revive stent (mean: 67.6 versus 58.9&#xa0;min; adjusted β-estimate: 11.6, 95%CI: 2.69–20.6) compared to the Trevo retriever. There were no outcome differences in the M1 subgroup analyses.</p> Conclusion <p>Differences in clinical, technical, and safety outcomes after EVT between the Trevo, Solitaire, Embotrap, and Revive stent retrievers were—although statistically significant—small. Treating physicians should use the stent retriever they are used to, and further studies with more strict patient selection should be conducted to validate these results.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Outcomes After Thrombectomy for Acute Ischemic Stroke Related to Type of Stent Retriever; a MR CLEAN Registry Study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月9日

查看全文
  • Robrecht R. M. M. Knapen,
  • Robert-Jan B. Goldhoorn,
  • Jan Albert Vos,
  • Bart J. Emmer,
  • Maarten Uyttenboogaart,
  • Jeannette Hofmeijer,
  • Wouter J. Schonewille,
  • Charles B. Majoie,
  • Yvo B. W. E. M. Roos,
  • Aad van der Lugt,
  • Diederik W. J. van Dippel,
  • Hester F. Lingsma,
  • Christiaan van der Leij,
  • Robert J. van Oostenbrugge,
  • Wim H. van Zwam,
  • Diederik W. J. Dippel,
  • Aad van der Lugt,
  • Charles B. L. M. Majoie,
  • Yvo B. W. E. M. Roos,
  • Robert J. van Oostenbrugge,
  • Wim H. van Zwam,
  • Jelis Boiten,
  • Jan Albert Vos,
  • Ivo G. H. Jansen,
  • Maxim J. H. L. Mulder,
  • Robert- Jan B. Goldhoorn,
  • Kars C. J. Compagne,
  • Manon Kappelhof,
  • Josje Brouwer,
  • Sanne J.den Hartog,
  • Wouter H. Hinsenveld,
  • Lotte van den Heuvel,
  • Diederik W. J. Dippel,
  • Bob Roozenbeek,
  • Aad van der Lugt,
  • Pieter Jan van Doormaal,
  • Charles B. L. M. Majoie,
  • Yvo B. W. E. M. Roos,
  • Bart J. Emmer,
  • Jonathan M. Coutinho,
  • Wouter J. Schonewille,
  • Jan Albert Vos,
  • Marieke J. H. Wermer,
  • Marianne A. A. van Walderveen,
  • Adriaan C. G. M. van Es,
  • Julie Staals,
  • Robert J. van Oostenbrugge,
  • Wim H. van Zwam,
  • Jeannette Hofmeijer,
  • Jasper M. Martens,
  • Geert J. Lycklama à Nijeholt,
  • Jelis Boiten,
  • Sebastiaan F. de Bruijn,
  • Lukas C. van Dijk,
  • H. Bart van der Worp,
  • Rob H. Lo,
  • Ewoud J. van Dijk,
  • Hieronymus D. Boogaarts,
  • J. de Vries,
  • Paul L. M. de Kort,
  • Julia van Tuijl,
  • Issam Boukrab,
  • Jo P. Peluso,
  • Puck Fransen,
  • Jan S. P. van den Berg,
  • Heleen M.den Hertog,
  • Boudewijn A. A. M. van Hasselt,
  • Leo A. M. Aerden,
  • René J. Dallinga,
  • Maarten Uyttenboogaart,
  • Omid Eschgi,
  • Reinoud P. H. Bokkers,
  • Tobien H. C. M. L. Schreuder,
  • Roel J. J. Heijboer,
  • Koos Keizer,
  • Rob A. R. Gons,
  • Lonneke S. F. Yo,
  • Emiel J. C. Sturm,
  • Tomas Bulut,
  • Paul J. A. M. Brouwers,
  • Anouk D. Rozeman,
  • Otto Elgersma,
  • Michel J. M. Remmers,
  • Thijs E. A. M. de Jong,
  • Charles B. L. M. Majoie,
  • Wim H. van Zwam,
  • Aad van der Lugt,
  • Geert J. Lycklama à Nijeholt,
  • Marianne A. A. van Walderveen,
  • Marieke E. S. Sprengers,
  • Sjoerd F. M. Jenniskens,
  • René van den Berg,
  • Albert J. Yoo,
  • Ludo F. M. Beenen,
  • Alida A. Postma,
  • Stefan D. Roosendaal,
  • Bas F. W. van der Kallen,
  • Ido R. van den Wijngaard,
  • Adriaan C. G. M. van Es,
  • Bart J. Emmer,
  • Jasper M. Martens,
  • Lonneke S. F. Yo,
  • Jan Albert Vos,
  • Joost Bot,
  • Pieter-Jan van Doormaal,
  • Anton Meijer,
  • Elyas Ghariq,
  • Reinoud P. H. Bokkers,
  • Marc P. van Proosdij,
  • G. Menno Krietemeijer,
  • Jo P. Peluso,
  • Hieronymus D. Boogaarts,
  • Rob Lo,
  • Wouter Dinkelaar,
  • Auke P. A. Appelman,
  • Bas Hammer,
  • Sjoert Pegge,
  • Anouk van der Hoorn,
  • Saman Vinke,
  • Sandra Cornelissen,
  • Christiaan van der Leij,
  • Rutger Brans,
  • Jeanette Bakker,
  • Maarten Uyttenboogaart,
  • Miou Koopman,
  • Lucas Smagge,
  • Olvert A. Berkhemer,
  • Jeroen Markenstein,
  • Eef Hendriks,
  • Patrick Brouwer,
  • Dick Gerrits,
  • Diederik W. J. Dippel,
  • Aad van der Lugt,
  • Charles B. L. M. Majoie,
  • Yvo B. W. E. M. Roos,
  • Robert J. van Oostenbrugge,
  • Wim H. van Zwam,
  • Geert J. Lycklama à Nijeholt,
  • Jelis Boiten,
  • Jan Albert Vos,
  • Wouter J. Schonewille,
  • Jeannette Hofmeijer,
  • Jasper M. Martens,
  • H. Bart van der Worp,
  • Rob H. Lo,
  • Robert J. van Oostenbrugge,
  • Jeannette Hofmeijer,
  • H. Zwenneke Flach,
  • Hester F. Lingsma,
  • Naziha el Ghannouti,
  • Martin Sterrenberg,
  • Wilma Pellikaan,
  • Rita Sprengers,
  • Marjan Elfrink,
  • Michelle Simons,
  • Marjolein Vossers,
  • Joke de Meris,
  • Tamara Vermeulen,
  • Annet Geerlings,
  • Gina van Vemde,
  • Tiny Simons,
  • Gert Messchendorp,
  • Nynke Nicolaij,
  • Hester Bongenaar,
  • Karin Bodde,
  • Sandra Kleijn,
  • Jasmijn Lodico,
  • Hanneke Droste,
  • Maureen Wollaert,
  • Sabrina Verheesen,
  • D. Jeurrissen,
  • Erna Bos,
  • Yvonne Drabbe,
  • Michelle Sandiman,
  • Nicoline Aaldering,
  • Berber Zweedijk,
  • Jocova Vervoort,
  • Eva Ponjee,
  • Sharon Romviel,
  • Karin Kanselaar,
  • Denn Barning,
  • Laurine van der Steen,
  • Esmee Venema,
  • Vicky Chalos,
  • Ralph R. Geuskens,
  • Tim van Straaten,
  • Saliha Ergezen,
  • Roger R. M. Harmsma,
  • Daan Muijres,
  • Anouk de Jong,
  • Olvert A. Berkhemer,
  • Anna M. M. Boers,
  • J. Huguet,
  • P. F. C. Groot,
  • Marieke A. Mens,
  • Katinka R. van Kranendonk,
  • Kilian M. Treurniet,
  • Manon L. Tolhuisen,
  • Heitor Alves,
  • Annick J. Weterings,
  • Eleonora L. F. Kirkels,
  • Eva J. H. F. Voogd,
  • Lieve M. Schupp,
  • Sabine L. Collette,
  • Adrien E. D. Groot,
  • Natalie E. LeCouffe,
  • Praneeta R. Konduri,
  • Haryadi Prasetya,
  • Nerea Arrarte-Terreros,
  • Lucas A. Ramos,
  • Nikki Boodt,
  • Anne F. A. V. Pirson,
  • Agnetha A. E. Bruggeman,
  • Nadinda A. M. van der Ende,
  • Rabia Deniz,
  • Susanne G. H. Olthuis,
  • Floor Pinckaers

摘要

Purpose

Endovascular treatment (EVT) with a stent retriever is known to be effective and safe in patients with acute ischemic stroke due to large vessel occlusion. We aimed to compare the most used stent retrievers in a nationwide registry of EVT-treated stroke patients (MR CLEAN Registry).

Methods

Patients with ischemic stroke due to large vessel occlusion, treated with stent retriever thrombectomy (each stent retriever with at least 100 EVTs) as first-line technique in the MR CLEAN Registry, were included. The primary outcome was the modified Rankin Scale (mRS) score at 90-day follow-up. Secondary outcomes included reperfusion (expanded Treatment In Cerebral Infarction [eTICI]), mortality at 90 days, symptomatic intracranial hemorrhage, National Institutes of Health Stroke Scale (NIHSS) score between 24 and 48 h post-EVT, and procedure time. With multivariable regression analyses, we calculated odds ratios (OR) and β-estimates to compare outcomes between the most frequently used stent retrievers, with adjustments for predefined variables. One subgroup analysis focused on the effect of the stent retriever on outcomes in M1 occlusions.

Results

Trevo (Stryker) was the most frequently used stent retriever (n = 1541, 70%). Other types were Solitaire (n = 301, 14%) (Medtronic), Embotrap (n = 255, 11%) (Cerenovus; Johnson&Johnson), and Revive (n = 103, 5.2%) (Cerenovus; Johnson&Johnson).

There was a slightly, but statistically significant, higher 90-day mRS score (adjusted common [ac]OR: 0.75, 95%CI: 0.57–0.99) and mortality rate (aOR: 1.77, 95%CI: 1.16–2.68) for the Solitaire and longer procedure times for the Revive stent (mean: 67.6 versus 58.9 min; adjusted β-estimate: 11.6, 95%CI: 2.69–20.6) compared to the Trevo retriever. There were no outcome differences in the M1 subgroup analyses.

Conclusion

Differences in clinical, technical, and safety outcomes after EVT between the Trevo, Solitaire, Embotrap, and Revive stent retrievers were—although statistically significant—small. Treating physicians should use the stent retriever they are used to, and further studies with more strict patient selection should be conducted to validate these results.

Graphical Abstract